Special Issue "Marine Alkaloids"

Quicklinks

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (15 September 2010)

Special Issue Editor

Guest Editor
Prof. Dr. Mercedes Álvarez
Institute for Research in Biomedicine (IRB Barcelona), Parc Científic de Barcelona, Baldiri Reixac 10, 08028 Barcelona, Spain
Website: http://www.pcb.ub.es/fama
E-Mail: mercedes.alvarez@irbbarcelona.org
Phone: +34 93 403 70 86
Fax: +34 93 403 71 26
Interests: marine natural products; bioactive natural products; alkaloids; synthesis; heterocycles

Special Issue Information

Dear Colleagues,

During the last thirty years an important number of secondary methabolites whith poliheterocyclic structure have been isolated from marine sources. This special issue will focus on the chemistry of marine alkaloids from diverse marine sources ranging from sponges, soft corals, tunicates, and other marine invertebrates. Yondelis® (trabectedin) is an antitumour agent of marine origin discovered in the colonial tunicate Ecteinascidia turbinate. It received marketing authorisation from the European Commission for the treatment of several cancer illness. It is currently produced by chemical synthesis. Yondelis® has a unique action mechanism. It binds to the minor groove of the DNA and interferes with cell division and the gene transcription processes and repair machinery of the DNA. The Issue entitled Marine Alkaloids will cover aspects as isolation, characterization, structure determination, activity, total synthesis, and mechanism of action of that family of compounds.

Prof. Dr. Mercedes Álvarez
Guest Editor

Keywords

  • marine alkaloid
  • isolation
  • activity
  • synthesis
  • heterocycles
  • bio-analogs

Published Papers (4 papers)

by , , , , , , ,  and
Mar. Drugs 2010, 8(6), 1769-1778; doi:10.3390/md8061769
Received: 28 April 2010; in revised form: 20 May 2010 / Accepted: 25 May 2010 / Published: 2 June 2010
Show/Hide Abstract | Cited by 2 | PDF Full-text (190 KB) | HTML Full-text | XML Full-text

by  and
Mar. Drugs 2010, 8(11), 2755-2780; doi:10.3390/md8112755
Received: 17 September 2010; in revised form: 27 October 2010 / Accepted: 4 November 2010 / Published: 5 November 2010
Show/Hide Abstract | Cited by 17 | PDF Full-text (1332 KB) | HTML Full-text | XML Full-text

by ,  and
Mar. Drugs 2010, 8(11), 2810-2836; doi:10.3390/md8112810
Received: 19 September 2010; in revised form: 3 November 2010 / Accepted: 8 November 2010 / Published: 10 November 2010
Show/Hide Abstract | Cited by 2 | PDF Full-text (1705 KB) | HTML Full-text | XML Full-text

by , , , , , ,  and
Mar. Drugs 2011, 9(2), 256-277; doi:10.3390/md9020256
Received: 30 December 2010; in revised form: 31 January 2011 / Accepted: 7 February 2011 / Published: 10 February 2011
Show/Hide Abstract | Cited by 3 | PDF Full-text (601 KB) | HTML Full-text | XML Full-text

Last update: 27 February 2014

Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert